Literature DB >> 23438060

Diagnostic potential of hepcidin testing in pediatrics.

Giuliana Cangemi1, Angela Pistorio, Maurizio Miano, Marco Gattorno, Maura Acquila, Maria Patrizia Bicocchi, Roberto Gastaldi, Francesca Riccardi, Cinzia Gatti, Francesca Fioredda, Michaela Calvillo, Giovanni Melioli, Alberto Martini, Carlo Dufour.   

Abstract

OBJECTIVES: Hepcidin, a peptide hormone released by hepatocytes into circulation is the main regulator of dietary iron absorption and cellular iron release. Although commercial tests are available, assay harmonization for hepcidin has not been yet reached, making reference intervals and consequent clinical decisions still elusive for each assay and specific population. The aim of this study is to set up hepcidin measurement in pediatric age and to investigate its potential usefulness in the diagnosis and management of iron disorders in children.
METHODS: Serum hepcidin was measured by using an automated commercial immunoassay. Reference values were obtained from 86 healthy children. Hepcidin was then evaluated in 52 children with diseases where this hormone was expected to be differently regulated.
RESULTS: Hepcidin values were 43.6 ng/mL median; 32-52.7 1-3 q: in males and 36.4 ng/mL median; 28.5-45.7 1-3 q: in females (P = 0.039). Hepcidin was significantly higher in postpubertal normal females than in normal males. Hepcidin resulted up-regulated in anemia of chronic disease of children affected by systemic Juvenile Idiopathic Arthritis and decreased after treatment with anakinra, an anti-interleukin-1 receptor antagonist. In iron deficiency anemia patients on oral iron supplementation and in β-thalassemia subjects, hepcidin levels were similar to those found in healthy subjects.
CONCLUSIONS: This study sets up reference values for pediatric population and shows that in normal controls serum hepcidin react differently to puberty in females vs. males. In addition, it suggests that serum hepcidin may discriminate microcytic inflammatory anemia of Juvenile Idiopathic Arthritis from iron deficiency anemia. Overall these findings may represent a helpful tool for future studies tailored to understand the role of hepcidin in management of iron disorders in children.
© 2013 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23438060     DOI: 10.1111/ejh.12081

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  16 in total

1.  Immunoassay-based serum hepcidin reference range measurements in healthy children: differences among age groups.

Authors:  Triantafyllia Sdogou; Charalampos Tsentidis; Dimitrios Gourgiotis; Antonios Marmarinos; Alexandra Gkourogianni; Ioannis Papassotiriou; Theodora Anastasiou; Lydia Kossiva
Journal:  J Clin Lab Anal       Date:  2014-03-22       Impact factor: 2.352

2.  Chronic inflammation and iron metabolism.

Authors:  Erin A Osterholm; Michael K Georgieff
Journal:  J Pediatr       Date:  2015-02-13       Impact factor: 4.406

3.  Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial.

Authors:  Meredith A Atkinson; Stephen P Juraschek; Michael S Bertenthal; Barbara Detrick; Susan L Furth; Edgar R Miller
Journal:  Pediatr Nephrol       Date:  2016-12-24       Impact factor: 3.714

Review 4.  From bench to bedside and back again: translational research in autoinflammation.

Authors:  Dirk Holzinger; Christoph Kessel; Alessia Omenetti; Marco Gattorno
Journal:  Nat Rev Rheumatol       Date:  2015-06-16       Impact factor: 20.543

5.  Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort.

Authors:  Meredith A Atkinson; Ji Young Kim; Cindy N Roy; Bradley A Warady; Colin T White; Susan L Furth
Journal:  Pediatr Nephrol       Date:  2014-11-08       Impact factor: 3.714

6.  Cord Blood Hepcidin: Cross-Sectional Correlates and Associations with Anemia, Malaria, and Mortality in a Tanzanian Birth Cohort Study.

Authors:  Elizabeth B Brickley; Natasha Spottiswoode; Edward Kabyemela; Robert Morrison; Jonathan D Kurtis; Angela M Wood; Hal Drakesmith; Michal Fried; Patrick E Duffy
Journal:  Am J Trop Med Hyg       Date:  2016-06-27       Impact factor: 2.345

Review 7.  Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks?

Authors:  Faekah Gohar; Christoph Kessel; Miha Lavric; Dirk Holzinger; Dirk Foell
Journal:  Arthritis Res Ther       Date:  2016-07-13       Impact factor: 5.156

8.  Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis.

Authors:  Jana Diestelhorst; Norman Junge; Danny Jonigk; Jerome Schlue; Christine S Falk; Michael P Manns; Ulrich Baumann; Elmar Jaeckel; Richard Taubert
Journal:  Sci Rep       Date:  2018-01-11       Impact factor: 4.379

9.  The effect of BCG on iron metabolism in the early neonatal period: A controlled trial in Gambian neonates.

Authors:  Sarah Prentice; Momodou W Jallow; Andrew M Prentice
Journal:  Vaccine       Date:  2015-05-07       Impact factor: 3.641

10.  Malaria and Age Variably but Critically Control Hepcidin Throughout Childhood in Kenya.

Authors:  Sarah H Atkinson; Sophie M Uyoga; Andrew E Armitage; Shivani Khandwala; Cleopatra K Mugyenyi; Philip Bejon; Kevin Marsh; James G Beeson; Andrew M Prentice; Hal Drakesmith; Thomas N Williams
Journal:  EBioMedicine       Date:  2015-08-08       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.